On february 11, 2025, the food and drug administration approved mirdametinib (gomekli, springworks therapeutics, inc.), a kinase inhibitor, for adult and pediatric patients 2 years of. [1] mirdametinib is a kinase inhibitor. Gomekli (mirdametinib) 1 mg and 2 mg capsules contain 1 mg and 2 mg mirdametinib, respectively, in gelatin capsule and the following inactive ingredients:
Indications, dosage, adverse reactions and pharmacology. [1][4] it is taken by. This era, which began at the close of the last ice age, represents.
Mirdametinib, sold under the brand name gomekli, is a medication used for the treatment of people with neurofibromatosis type 1. Gomekli package insert / prescribing information for healthcare professionals. Gomekli capsules and tablets for oral suspension contain mirdametinib, a kinase inhibitor.